These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38077638)

  • 1. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer.
    Mullin G; Sternschuss M; Landman Y; Sulkes A; Brenner B
    World J Gastrointest Oncol; 2023 Nov; 15(11):1913-1924. PubMed ID: 38077638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.
    Ferrarotto R; Machado K; Mak MP; Shah N; Takahashi TK; Costa FP; Overman MJ; Kopetz S; Hoff PM
    Eur J Cancer; 2012 Apr; 48(6):820-6. PubMed ID: 22330318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
    Miranda MB; Hartmann JT; Al-Batran SE; Kripp M; Gencer D; Hochhaus A; Hofheinz RD; Merx K
    J Cancer Res Clin Oncol; 2014 May; 140(5):829-37. PubMed ID: 24556803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C.
    Zygulska AL; Krzemieniecki K
    Neoplasma; 2015; 62(5):793-7. PubMed ID: 26278141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G
    Anticancer Res; 2013 Jun; 33(6):2743-6. PubMed ID: 23749935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
    Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
    Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
    Chong G; Dickson JL; Cunningham D; Norman AR; Rao S; Hill ME; Price TJ; Oates J; Tebbutt N
    Br J Cancer; 2005 Sep; 93(5):510-4. PubMed ID: 16091760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.
    Vrdoljak E; Omrcen T; Boban M; Hrepic D
    J BUON; 2008; 13(4):513-8. PubMed ID: 19145672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.
    Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M
    Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
    BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
    Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A
    Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
    Seal BS; Anderson S; Shermock KM
    J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
    Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
    Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
    J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
    Vrdoljak E; Boban M; Omrcen T; Hrepic D; Fridl-Vidas V; Boskovic L
    Neoplasma; 2011; 58(2):172-8. PubMed ID: 21275468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
    Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
    BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.